Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review

Author： Wong Michael K.   Yang Hongbo   Signorovitch James E.   Wang Xufang   Liu Zhimei   Liu Nathan S.   Qi Cynthia Z.   George Daniel J.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.30, Iss.4, 2014-04, pp. : 537-545

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma

By  

Oncology, Vol. 82, Iss. 6, 2012-06 ,pp. : 333-340

Karger

Access to resources Recommend Favorite

Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-05 ,pp. : 34-41

Karger

Access to resources Recommend Favorite

Duration of Targeted Therapy for Metastatic Renal Cell Carcinoma: A Review of Current Practices

By  

Oncology, Vol. 82, Iss. 4, 2012-03 ,pp. : 189-196

Karger

Access to resources Recommend Favorite

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

By  

CANCER, Vol. 119, Iss. 18, 2013-09 ,pp. : 3377-3384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stevens-Johnson Syndrome Induced by Sorafenib for Metastatic Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 91, Iss. 4, 2013-08 ,pp. : 482-483

Karger

Access to resources Recommend Favorite